We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sygnature Chemical Services and Cyprotex Establish Strategic Alliance

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sygnature Chemical Services and Cyprotex Establish Strategic Alliance"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Under the terms of the agreement, Sygnature and Cyprotex will collaborate to provide a fully-integrated discovery chemistry/DMPK service to accelerate their clients’ drug discovery projects into development.

Dr Anthony Baxter, Chief Executive Offer at Cyprotex said, "We are pleased to have formed a strategic alliance with Sygnature.  Over the past 5 years, they have established a reputation for high-quality medicinal chemistry, and for the intellectual input they contribute into projects.  Cyprotex is known as a centre of excellence for ADME/PK services and we are the first choice CRO for many biotech and big pharma companies.  Sygnature is a centre of excellence for medicinal chemistry and has an impressive track record.  By working closely together with our customers, who will be experts in their particular therapeutic project field, we are confident that we can accelerate projects forward more effectively than CROs that offer a one-stop-shop approach.  My colleagues and I are looking forward to working with the Sygnature team to offer an outstanding fully-integrated discovery chemistry/ADME/DMPK service.”

Commenting on the partnership, Dr Simon Hirst, Sygnature’s CEO said, “Cyprotex has an enviable reputation as a CRO which provides premium ADME/PK services, so I am delighted that we will be working together to offer clients an exceptional, integrated discovery chemistry/DMPK service.  At Sygnature we strongly believe that modern drug discovery requires the marriage of medicinal chemistry, ADME and biology.  Our medicinal chemists are experienced in using ADME data to drive programmes forward and into proof-of-concept in vivo studies.  For the past 18 months, Sygnature and Cyprotex have been collaborating on a drug discovery programme for a customer.  Hence, scientists from both organisations already know each other well and have established project management systems in place.  I am confident that other customers will see the advantages of a medicinal chemistry-driven service which takes advantage of a faster turnaround of ADME/DMPK data to help determine the discovery chemistry strategy of the project.”